Adjuvant Chemotherapy Bladder-sparing Chemoradiation Enhanced Recovery after Surgery Muscle-invasive Bladder Cancer Neoadjuvant Chemotherapy Radical Cystectomy Transurethral Resection of Bladder Tumor Trimodal Urothelial Carcinoma of Bladder Variant Histology

Bladder-sparing strategy Clinical complete response Localized muscle-invasive bladder cancer Neoadjuvant Systemic treatment

Humans *Gemcitabine Docetaxel/therapeutic use BCG Vaccine/adverse effects Adjuvants Immunologic *Urinary Bladder Neoplasms/therapy Administration Intravesical Neoplasm Invasiveness Neoplasm Recurrence Local

Humans *Adjuvants Immunologic/therapeutic use/adverse effects Administration Intravesical Neoplasm Recurrence Local/epidemiology *Urinary Bladder Neoplasms/pathology Drug Administration Schedule Bcg Cvnmi Desabastecimiento Dosis completa Dosis reducida Full dose Nmibc Reduced dose Shortage

Humans *Carcinoma Transitional Cell *Urinary Bladder Neoplasms/pathology Retrospective Studies BCG Vaccine/therapeutic use Administration Intravesical Adjuvants Immunologic *Organ Transplantation Neoplasm Invasiveness Neoplasm Recurrence Local/pathology Bcg Bladder cancer Chemotherapy Mitomycin Transplanted patients

Cisplatin/adverse effects Humans *Immunotherapy/adverse effects/methods *Muscles/pathology *Neoadjuvant Therapy/adverse effects Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/pathology/therapy chemoimmunotherapy immunotherapy meta-analysis muscle-invasive bladder cancer (MIBC) neoadjuvant commercial or financial relationships that could be construed as a potential conflict of interest.

Humans *Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/pathology Infusions Intra-Arterial Chemotherapy Adjuvant Adverse Reactions bladder cancer intra-arterial chemotherapy meta-analysis prognosis

Bladder cancer neoadjuvant chemotherapy radical cystectomy systematic review variant histology urothelial cancer

Adjuvants Immunologic Administration Intravesical BCG Vaccine/therapeutic use Bayes Theorem *Covid-19 Duration of Therapy Humans *Mycobacterium bovis Neoplasm Invasiveness Neoplasm Recurrence Local/drug therapy Network Meta-Analysis Pandemics *Urinary Bladder Neoplasms/drug therapy *Urology

adjuvant immune checkpoint inhibitors muscle-invasive bladder cancer neoadjuvant

Humans *Carcinoma Transitional Cell/radiotherapy/surgery/drug therapy *Urinary Bladder Neoplasms Radiotherapy Adjuvant Retrospective Studies Prospective Studies Neoplasm Recurrence Local adjuvant radiotherapy external beam genitourinary locoregional control meta-analysis proximal ureter renal pelvis survival systematic review upper tract urothelial carcinoma

*Cystectomy Humans *Neoadjuvant Therapy Neoplasm Staging Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery

adjuvant chemotherapy bladder cancer cystectomy

Antineoplastic Combined Chemotherapy Protocols/therapeutic use *Carcinoma Transitional Cell/pathology Cisplatin/therapeutic use Cystectomy Humans Muscles/pathology Neoadjuvant Therapy Neoplasm Invasiveness *Urinary Bladder Neoplasms/pathology Bladder cancer Muscle-invasive Urothelial from MSD and BMS and Speaker and Other from AstraZecena. BPV reports Advisory Board Speaker and Other from Astellas Roche BMS and Merk-Pfizer Advisory Board and Other from Ipsen Advisory Board and Speaker from EUSA and MSD and Advisory Board from Sanofi. IPF report Advisory Board Speaker and Other from Pfizer Speaker and Other from Ipsen and Roche Advisory Board from EUSA and BMS and Speaker from Novartis and MSD. OFC reports Advisory Board and Speaker from Ipsen and Astellas Advisory Board from BMS and Pfizer-Merck and Speaker from AstraZeneca. AGA has received research funding from Astellas travel grants from Astellas Jansen Sanofi BMS Roche Pfizer and Ipsen and honoraria for speaker engagements advisory boards and continuous medical education from Janssen Astellas Sanofi Bayer Roche Ipsen BMS MSD Pfizer Eusa Pharma Eisai and AstraZeneca. JAA reports honoraria from Astellas Pfizer and BMS conulting or advisory role from Pfizer Astellas Janssen-Cilag MSD Oncology BMS Merck AstraZeneca Bayer and Eisai and Research Funding from BMS. RMB SVE CCD and MDS have nothing to disclose.

Cystectomy France Humans Lymphatic Irradiation Palliative Care Patient Positioning Radiation Oncology Radiotherapy Dosage Radiotherapy Adjuvant Radiotherapy Conformal Urinary Bladder Neoplasms/diagnostic imaging/pathology/*radiotherapy/surgery Bladder cancer Cancers de la vessie Chemoradiation Chimioradiothérapie French society for radiation oncology Guidelines Radiation therapy Radiothérapie Recommandations Société française de radiothérapie oncologique

Humans *Cystectomy/methods *Urinary Bladder Neoplasms/radiotherapy/surgery Urinary Bladder Radiotherapy Adjuvant/methods Prospective Studies Margins of Excision

Antineoplastic Combined Chemotherapy Protocols/adverse effects Bayes Theorem *Carcinoma Transitional Cell/drug therapy/surgery Humans Network Meta-Analysis *Urinary Bladder Neoplasms/drug therapy/surgery Ici Pd-1 Pd-l1 adjuvant therapy chemotherapy urothelial carcinoma

Adjuvants Immunologic/therapeutic use Administration Intravesical Aged BCG Vaccine/therapeutic use Humans *Mycobacterium bovis Neoplasm Invasiveness Neoplasm Recurrence Local *Urinary Bladder Neoplasms

*Carcinoma Transitional Cell/pathology/radiotherapy Humans *Kidney Neoplasms Kidney Pelvis/pathology Prognosis *Ureteral Neoplasms/pathology *Urinary Bladder Neoplasms Adjuvant radiotherapy Prognostic Radiotherapy Survival Upper urinary tract urothelial carcinoma

Chemotherapy Adjuvant Cisplatin/therapeutic use Female Humans Male Muscles Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/drug therapy *Bladder cancer *Chemotherapy *Individual participant data *Meta-analysis *Systematic review